Jill Kolesar

5.9k total citations
192 papers, 4.3k citations indexed

About

Jill Kolesar is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Jill Kolesar has authored 192 papers receiving a total of 4.3k indexed citations (citations by other indexed papers that have themselves been cited), including 102 papers in Oncology, 73 papers in Molecular Biology and 58 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Jill Kolesar's work include Lung Cancer Treatments and Mutations (40 papers), Lung Cancer Research Studies (26 papers) and Cancer therapeutics and mechanisms (22 papers). Jill Kolesar is often cited by papers focused on Lung Cancer Treatments and Mutations (40 papers), Lung Cancer Research Studies (26 papers) and Cancer therapeutics and mechanisms (22 papers). Jill Kolesar collaborates with scholars based in United States, India and Canada. Jill Kolesar's co-authors include George Wilding, Jens C. Eickhoff, Amyé Tevaarwerk, Frederick R. Ueland, Joan H. Schiller, Dona Alberti, Anne M. Traynor, Rebecca Marnocha, Glenn Liu and Jon Hiles and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Jill Kolesar

184 papers receiving 4.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jill Kolesar United States 37 2.0k 1.8k 936 620 368 192 4.3k
Jan H. Beumer United States 40 2.3k 1.1× 2.1k 1.2× 683 0.7× 489 0.8× 417 1.1× 234 4.8k
Grace K. Dy United States 37 2.3k 1.1× 2.3k 1.3× 1.5k 1.6× 644 1.0× 420 1.1× 213 4.7k
Norma O’Donovan Ireland 36 2.2k 1.1× 2.3k 1.3× 637 0.7× 838 1.4× 404 1.1× 116 4.3k
Guido Bocci Italy 42 2.4k 1.2× 2.6k 1.5× 1.0k 1.1× 1.2k 2.0× 428 1.2× 206 5.8k
Sarah Danson United Kingdom 31 1.7k 0.8× 2.2k 1.2× 1.1k 1.2× 485 0.8× 668 1.8× 120 4.4k
Percy Ivy United States 36 1.9k 0.9× 1.5k 0.8× 883 0.9× 869 1.4× 371 1.0× 120 4.5k
Joseph Ciccolini France 36 1.6k 0.8× 2.4k 1.4× 683 0.7× 677 1.1× 377 1.0× 196 4.5k
S. Gail Eckhardt United States 36 2.6k 1.3× 2.5k 1.4× 1.1k 1.2× 1.2k 1.9× 624 1.7× 105 5.3k
Devalingam Mahalingam United States 41 2.9k 1.4× 2.0k 1.1× 711 0.8× 922 1.5× 655 1.8× 186 5.4k
Bert L. Lum United States 38 1.8k 0.9× 2.4k 1.3× 818 0.9× 412 0.7× 363 1.0× 83 4.7k

Countries citing papers authored by Jill Kolesar

Since Specialization
Citations

This map shows the geographic impact of Jill Kolesar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jill Kolesar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jill Kolesar more than expected).

Fields of papers citing papers by Jill Kolesar

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jill Kolesar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jill Kolesar. The network helps show where Jill Kolesar may publish in the future.

Co-authorship network of co-authors of Jill Kolesar

This figure shows the co-authorship network connecting the top 25 collaborators of Jill Kolesar. A scholar is included among the top collaborators of Jill Kolesar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jill Kolesar. Jill Kolesar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Cao, Connie D., J. Robert McCorkle, Derek B. Allison, et al.. (2025). M1 macrophage-engineered vesicles have anti-cancer activity in ovarian cancer. Cancer Nanotechnology. 16(1). 1 indexed citations
2.
Damerla, Rama Rao, Murali Munisamy, Surulivelrajan Mallayasamy, et al.. (2025). Influence of genetic polymorphisms on gefitinib pharmacokinetics and adverse drug reactions in non-small cell lung cancer patients. Cancer and Metastasis Reviews. 44(4). 82–82.
3.
McCorkle, J. Robert, et al.. (2024). Antineoplastic Drug Synergy of Artesunate with Navitoclax in Models of High-Grade Serous Ovarian Cancer. Cancers. 16(7). 1321–1321. 6 indexed citations
4.
Brock, Pamela, Taina T. Nieminen, Carlos H.F. Chan, et al.. (2024). CHEK2 Founder Variants and Thyroid Cancer Risk. Thyroid. 34(4). 477–483. 4 indexed citations
5.
Kim, KyungMann, et al.. (2023). Non-melanoma skin cancer event rates in a formalized clinical trial setting: considerations for clinical trial design. European Journal of Cancer Prevention. 33(1). 69–72. 1 indexed citations
6.
Chen, Quan, Bin Huang, Abigail Anderson, et al.. (2023). Association of first primary cancer with risk of subsequent primary cancer among survivors of adult-onset cancers in Kentucky and Appalachian Kentucky. Frontiers in Oncology. 13. 1193487–1193487. 3 indexed citations
7.
Hill, Kristen S., Charles J. Bailey, Michael J. Cavnar, et al.. (2023). Creation of EGD-Derived Gastric Cancer Organoids to Predict Treatment Responses. Cancers. 15(11). 3036–3036. 4 indexed citations
8.
Myint, Zin, William H. St. Clair, Stephen E. Strup, et al.. (2023). A Phase I Dose Escalation and Expansion Study of Epidiolex (Cannabidiol) in Patients with Biochemically Recurrent Prostate Cancer. Cancers. 15(9). 2505–2505. 6 indexed citations
9.
Anand, Namrata, et al.. (2023). Macrophage Repolarization as a Therapeutic Strategy for Osteosarcoma. International Journal of Molecular Sciences. 24(3). 2858–2858. 45 indexed citations
10.
Zhang, Shulin, Nan Lin, James W. Keck, et al.. (2022). Real-World Evaluation of a Population Germline Genetic Screening Initiative for Family Medicine Patients. Journal of Personalized Medicine. 12(8). 1297–1297. 3 indexed citations
11.
McCorkle, J. Robert, J Górski, Jinpeng Liu, et al.. (2021). Lapatinib and poziotinib overcome ABCB1-mediated paclitaxel resistance in ovarian cancer. PLoS ONE. 16(8). e0254205–e0254205. 18 indexed citations
12.
Larson, Kara, et al.. (2020). EGFR testing and erlotinib use in non-small cell lung cancer patients in Kentucky. PLoS ONE. 15(8). e0237790–e0237790. 9 indexed citations
13.
Bertino, Erin M., Ryan D. Gentzler, Jill Kolesar, et al.. (2020). Phase IB Study of Osimertinib in Combination with Navitoclax in EGFR-mutant NSCLC Following Resistance to Initial EGFR Therapy (ETCTN 9903). Clinical Cancer Research. 27(6). 1604–1611. 31 indexed citations
14.
Kolesar, Jill, Heather Green, Douglas Laux, et al.. (2019). A Randomized, Placebo-Controlled, Double-Blind, Dose Escalation, Single Dose, and Steady-State Pharmacokinetic Study of 9cUAB30 in Healthy Volunteers. Cancer Prevention Research. 12(12). 903–912. 5 indexed citations
15.
Becher, Oren J., Shakeel Modak, Brian H. Kushner, et al.. (2017). A phase I study of single-agent perifosine for recurrent or refractory pediatric CNS and solid tumors. PLoS ONE. 12(6). e0178593–e0178593. 36 indexed citations
16.
LoConte, Noelle K., Albiruni R. Abdul Razak, Percy Ivy, et al.. (2014). A multicenter phase 1 study of γ -secretase inhibitor RO4929097 in combination with capecitabine in refractory solid tumors. Investigational New Drugs. 33(1). 169–176. 33 indexed citations
17.
Zhang, Yang, Lee C. Vermeulen, & Jill Kolesar. (2013). Stability of stock and diluted rituximab. American Journal of Health-System Pharmacy. 70(5). 436–438. 17 indexed citations
18.
19.
20.
Kolesar, Jill, et al.. (2006). Role of trastuzumab in adjuvant therapy for locally invasive breast cancer. American Journal of Health-System Pharmacy. 63(6). 527–533. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jan H. Beumer Breakdown of academic impact, for papers by Grace K. Dy Breakdown of academic impact, for papers by Norma O’Donovan Breakdown of academic impact, for papers by Guido Bocci Breakdown of academic impact, for papers by Sarah Danson Breakdown of academic impact, for papers by Percy Ivy Breakdown of academic impact, for papers by Joseph Ciccolini Breakdown of academic impact, for papers by S. Gail Eckhardt Breakdown of academic impact, for papers by Devalingam Mahalingam Breakdown of academic impact, for papers by Bert L. Lum
Rankless by CCL
2026